跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 7,408 条关于
“menin-KMT2A/MLL”
全部
7,408
临床试验
6,363
药物
481
机构
34
资讯
530
去年
Over 120 Pipeline Therapies Target Acute Myeloid Leukemia as Research Intensifies
9个月前
Menin Inhibitors Show Promise as Targeted Therapy for Aggressive KMT2A-Rearranged Acute Leukemia
2年前
Kura Oncology's Menin Inhibitor Ziftomenib Receives FDA IND Clearance for Advanced GIST
去年
Menin Inhibitors Market Poised for Strong Growth as REVUFORJ Becomes First FDA-Approved Drug in Class
去年
Kura Oncology and Kyowa Kirin Partner to Advance Ziftomenib for Acute Leukemias
去年
Ziftomenib Shows Promise in Treatment-Resistant Acute Myeloid Leukemia
去年
Ziftomenib Plus Intensive Induction Shows Promise in NPM1-Mutated AML
去年
FDA Approves Syndax's Revuforj, a Novel Menin Inhibitor, for KMT2A-Rearranged Leukemia
去年
FDA Approves Syndax's Revuforj as First Menin Inhibitor for KMT2A-Rearranged Leukemia
去年
FDA Approves Revumenib (Revuforj) as First Menin Inhibitor for KMT2A-Rearranged Acute Leukemia
第 1 页,共 53 页
上一页
下一页